Last reviewed · How we verify
FEC
FEC is a combination chemotherapy regimen that uses three cytotoxic agents to damage cancer cell DNA and inhibit cell division.
FEC is a combination chemotherapy regimen that uses three cytotoxic agents to damage cancer cell DNA and inhibit cell division. Used for Breast cancer (adjuvant and neoadjuvant treatment), Metastatic breast cancer.
At a glance
| Generic name | FEC |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Drug class | Combination chemotherapy regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
FEC combines fluorouracil (a thymidylate synthase inhibitor), epirubicin (a topoisomerase II inhibitor and intercalating agent), and cyclophosphamide (an alkylating agent). Together, these agents work synergistically to disrupt DNA synthesis and repair, leading to cancer cell death. The combination is designed to provide broad cytotoxic activity against rapidly dividing cells.
Approved indications
- Breast cancer (adjuvant and neoadjuvant treatment)
- Metastatic breast cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Alopecia
- Mucositis
- Cardiotoxicity
- Fatigue
Key clinical trials
- Proteomic Signature in Breast Cancer: Correlation With Tumor Response to Neo-adjuvant Chemotherapy (NA)
- Role of Pancreatic Exocrine Secretion in Weight Gain After Pancreas Transplantation
- Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer (PHASE2)
- Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant/Adjuvant Setting (REaCT-TNBC) (PHASE4)
- Single and Multiple Ascending Dose Study to Evaluate AMG 786 in Healthy Participants and Participants With Obesity (PHASE1)
- Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older (PHASE1, PHASE2)
- PureWick™ France and U.S. At-Home Pilot Study (NA)
- A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |